Cadence Design Systems and Treeline Biosciences Partner to Launch AI-Driven ROCS X Platform for Trillion-Molecule Drug Discovery
Reuters
Sep 25
Cadence Design Systems and Treeline Biosciences Partner to Launch AI-Driven ROCS X Platform for Trillion-Molecule Drug Discovery
Cadence Design Systems Inc., through its Cadence Molecular Sciences (OpenEye) business unit, has partnered with Treeline Biosciences to develop and validate ROCS X, an AI-driven virtual screening platform for drug discovery. This collaboration enabled the creation of ROCS X, which allows scientists to conduct 3D searches across trillions of drug-like molecules-vastly expanding the scale of chemical space that can be explored for potential therapeutics. Treeline Biosciences used ROCS X to identify and physically source over 150 novel, synthesizable compounds as drug candidates, accelerating their efforts to address serious medical conditions such as cancer. Early access to ROCS X is now available, with general availability expected in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadence Design Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250925980347) on September 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.